Literature DB >> 31042431

Straight-to-test for the two-week-wait colorectal cancer pathway under the updated NICE guidelines reduces time to cancer diagnosis and treatment.

J Christopher1, T R Flint2, H Ahmed3, N Dhir3, R Li3, K Macfarland4, Dzs Ng5, Jmk Ng6, C O'Neill7, A Te Water Naudé8, K Sloan9, N R Hall9, M P Powar9.   

Abstract

INTRODUCTION: The 2015 National Institute for Health and Care Excellence guidelines widened the referral criteria for the two-week-wait pathway for suspected lower gastrointestinal cancer. We implemented a straight-to-test protocol to accommodate the anticipated increase in referrals. We evaluated the impact of these changes for relevant pathway metrics and clinical outcomes using a retrospective cohort study with historic controls.
MATERIALS AND METHODS: We analysed data from all patients referred to a teaching hospital via the two-week-wait pathway for suspected lower gastrointestinal cancer under the previous guidelines between 1 March and 31 August 2015 compared with the same period in 2016, when the updated guidelines and straight-to-test protocol had been implemented.
RESULTS: In the 2015 cohort, there were 64 cancer diagnoses from 664 referrals (9.6% pick-up) compared with 58 cancer diagnoses from 954 referrals in the 2016 cohort (6.1% pick-up). Our straight-to-test protocol reduced the median time to cancer diagnosis by 12.5 days (P < 0.001) and reduced the median time to cancer treatment by 7.5 days (P < 0.05) An increased proportion of non-colorectal cancers were diagnosed in 2016 compared with 2015, (37.9% vs 17.2%, P < 0.05) and more adenomas were removed in 2016 compared with 2015 (377 vs 193). DISCUSSION AND
CONCLUSION: Our straight-to-test protocol has resulted in a reduction in times to cancer diagnosis and cancer treatment, despite an increase in the number of referrals. The new referral criteria have considerable resource implications, but their implementation did not result in an increase in the total number of cancers diagnosed.

Entities:  

Keywords:  Colonoscopy; Diagnosis; Gastrointestinal neoplasms; Neoplasms; Surgery

Mesh:

Year:  2019        PMID: 31042431      PMCID: PMC6513371          DOI: 10.1308/rcsann.2019.0022

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  18 in total

1.  Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer.

Authors:  D M Hemingway; J Jameson; M J Kelly
Journal:  Colorectal Dis       Date:  2006-05       Impact factor: 3.788

2.  Surveillance guidelines after removal of colorectal adenomatous polyps.

Authors:  W S Atkin; B P Saunders
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

3.  Straight to colonoscopy: the ideal patient pathway for the 2-week suspected cancer referrals?

Authors:  Andrew D Beggs; Ravinda D Bhate; Shashi Irukulla; Mayen Achiek; A Muti Abulafi
Journal:  Ann R Coll Surg Engl       Date:  2010-11-12       Impact factor: 1.891

4.  Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.

Authors:  John M Inadomi; Sandeep Vijan; Nancy K Janz; Angela Fagerlin; Jennifer P Thomas; Yunghui V Lin; Roxana Muñoz; Chim Lau; Ma Somsouk; Najwa El-Nachef; Rodney A Hayward
Journal:  Arch Intern Med       Date:  2012-04-09

Review 5.  The 2-week wait for suspected cancer: time for a rethink?

Authors:  S J Hanna; A Muneer; K H Khalil
Journal:  Int J Clin Pract       Date:  2005-11       Impact factor: 2.503

Review 6.  Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis.

Authors:  Petra Jellema; Daniëlle A W M van der Windt; David J Bruinvels; Christian D Mallen; Stijn J B van Weyenberg; Chris J Mulder; Henrica C W de Vet
Journal:  BMJ       Date:  2010-03-31

7.  The Department of Health's "two week standard" for bowel cancer: is it working?

Authors:  K Flashman; D P O'Leary; A Senapati; M R Thompson
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

8.  The 'straight to test' initiative reduces both diagnostic and treatment waiting times for colorectal cancer: outcomes after 2 years.

Authors:  S Mukherjee; G Fountain; M Stalker; J Williams; T R C Porrett; P J Lunniss
Journal:  Colorectal Dis       Date:  2010-10       Impact factor: 3.788

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care.

Authors:  M L Tørring; M Frydenberg; R P Hansen; F Olesen; W Hamilton; P Vedsted
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

View more
  5 in total

1.  Role of the faecal immunochemical test in patients with risk-stratified suspected colorectal cancer symptoms: A systematic review and meta-analysis to inform the ACPGBI/BSG guidelines.

Authors:  Richard Booth; Rachel Carten; Nigel D'Souza; Marie Westwood; Jos Kleijnen; Muti Abulafi
Journal:  Lancet Reg Health Eur       Date:  2022-10-03

2.  COVID-19 recovery: tackling the 2-week wait colorectal pathway backlog by optimising CT colonography utilisation.

Authors:  N O'Donohoe; S Jamal; J Cope; L Strom; S Ryan; J W Nunoo-Mensah
Journal:  Clin Radiol       Date:  2020-09-21       Impact factor: 2.350

3.  Patient experiences of the urgent cancer referral pathway-Can the NHS do better? Semi-structured interviews with patients with upper gastrointestinal cancer.

Authors:  Anna Haste; Mark Lambert; Linda Sharp; Richard Thomson; Sarah Sowden
Journal:  Health Expect       Date:  2020-09-28       Impact factor: 3.377

Review 4.  Endorobots for Colonoscopy: Design Challenges and Available Technologies.

Authors:  Luigi Manfredi
Journal:  Front Robot AI       Date:  2021-07-14

5.  "One stop" clinic for upper gastrointestinal cancer-an alternative to "straight to test" referrals?

Authors:  Marina Yiasemidou; Ross Lathan; Manfred Lambertz; Chitakattil Oommen; Ian Chetter
Journal:  Ir J Med Sci       Date:  2021-07-20       Impact factor: 1.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.